LOUISVILLE, CO--(Marketwire - November 01, 2008) - Four-week Phase 2 clinical trial data show that GI-5005, GlobeImmune's hepatitis C virus (HCV) targeted molecular immunogen (Tarmogen®), doubled viral clearance overall and in all major subgroups and doubled the rapid virologic response (RVR) rate in naïve patients with high viral load. The study compared GI-5005 plus standard of care (SOC) -- pegylated-interferon plus ribavirin -- versus SOC alone in patients with chronic genotype 1 hepatitis C infection.
